Align Technology (ALGN) PT Raised to $175 at Morgan Stanley; Huge At-Home Ortho Opportunity

June 19, 2017 7:54 AM EDT
Get Alerts ALGN Hot Sheet
Price: $343.10 -4.66%

Rating Summary:
    21 Buy, 5 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 32 | New: 9
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Morgan Stanley raised its price target on Align Technology (NASDAQ: ALGN) to $175.00 (from $150.00) while maintaining a Overweight rating, citing the at-home opportunity.

Analyst Steve Beuchaw has a strategic imperative to access an incremental ~150 million case doctor-directed at-home ortho opportunity globally that can grow the TAM by >10x.

Beuchaw said the company's core business opportunity of taking share in the 10 million case per year orthodontic market from a base of ~8%, is appealing and supports their base business valuation of $157 per share. However, this is small in comparison to the estimate of a 300 million case global prevalence pool for malocclusions treatable at-home with clear aligners.

"We estimate ALGN can capture 50% of ~350k at-home cases in the US in 2020 and 70% longer-term, which would contribute ~$50mn/13% of incremental cash flow by 2020," the analyst commented.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Hot Comments

Related Entities

Morgan Stanley